Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Heart and Blood Diseases

Immune System Diseases

Rare Diseases

Syndrome

Leukemia

Preleukemia

Myelodysplastic Syndromes

Multiple Myeloma

Neoplasms, Plasma Cell

Hematologic Neoplasms

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Bone Marrow Diseases

Chronic Graft Versus Host Disease

Acute Graft Versus Host Disease

Patients with Myltiple Myeloma, symptomatic or asymptomatic

Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)

Patients with Chronic Lymphocytic Leukemia

Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days

Geriatric Assessment of Health Status Scale administration

Jose Luis Garcia, PhD

The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly functional patients, they do not present co morbidities and could benefit from oncology therapies.

Treatment planning must consider several health indices that are useful when it comes to detecting geriatric problems that could affect the patient's treatment experience. The complete comprehensive geriatric evaluation stands out as cornerstone among other validated tools that do not work as isolated instruments; however, its length and complexity may hinder its routine use in clinical practice for decision making.

The purpose of this study is to validate a comprehensive health status assessment scale in elderly patients (≥65 years) with hematological malignancies that, while integrating the essential dimensions of geriatric assessment and, with the same precision as the currently available valid tools, is shorter and easier to apply, so it can be incorporated into the daily practice and that aids in clinical decision making objectively.

If so, this information would help identify patients that could benefit from a specific oncology treatment, thus contributing to developing a targeted intervention plan and to optimizing the cancer results in this patient population.

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

A composite variable comprised of all the dimensions that make up the GHA questionnaire will be obtained on stable patients as a result of the implementation of a questionnaire by two independent evaluators: one investigator and one duly trained health professional.

Celgene

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies	NCT02164071	Myelodysplastic... Leukemia Myeloi... Multiple Myelom... Leuklemia, Lymp...	Geriatric Asses...	65 Years -	Celgene
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies	NCT02164071	Myelodysplastic... Leukemia Myeloi... Multiple Myelom... Leuklemia, Lymp...	Geriatric Asses...	65 Years -	Celgene

Spots Global Cancer Trial Database for leuklemia, lymphocytic, chronic